Failure to develop HIV infection after receipt of HIV-contaminated blood and postexposure prophylaxis.
Katzenstein
T L
TL
National University Hospital Rigshospitalet and State Serum Institute, Copenhagen, Denmark. terese@rh.dk
Dickmeiss
E
E
Aladdin
H
H
Hede
A
A
Nielsen
C
C
Nielsen
H
H
Jørgensen
L B
LB
Gerstoft
J
J
D000293:Adolescent; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006678:HIV / Q000302:isolation & purification; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission* / Q000821:virology; D006801:Humans; D019469:Indinavir / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D019888:Nelfinavir / Q000627:therapeutic use; D065227:Transfusion Reaction; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir; D019888:Nelfinavir